Companies Dominating the Hyaluronidase Landscape
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PrimaPharm Inc.
- Valeant Pharmaceuticals
- Halozyme Therapeutics
- CooperSurgical Fertility Companies
- Amphastar Pharmaceuticals Inc.
- Shreya Life Science
- Bausch & Lomb Incorporated
- Stemcell Technologies Inc.
- Anika Therapeutics Inc.
- Alteogen Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of hyaluronidase is assessed at USD 1.15 billion.
The hyaluronidase market size was valued at USD 1.07 billion in 2024 and is expected to reach USD 3.13 billion by 2037, registering around 8.6% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of chronic disease and increasing support by the government on its research and development activities will boost the market growth.
North America industry is estimated to dominate majority revenue share of 33% by 2037, due to increasing number of vendors in the region.
The major players in the market are Halozyme Therapeutics, CooperSurgical Fertility Companies, Amphastar Pharmaceuticals Inc., Shreya Life Science, Bausch & Lomb Incorporated, Stemcell Technologies Inc., Anika Therapeutics Inc., Alteogen Inc., and others.
